Trial Profile

Effects of Sodium Glucose Co-Transporter 2 Inhibitor Therapy on Pancreatic and hepatic fat content using 3.0 Tesla Magnetic Resonance Imaging Proton Density Fat Fraction Software in patients of Type 2 Diabetes Mellitus when treated according to current guidelines Protocol: Prospective Open Label Case Control 16 weeks Proof of Concept Study.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Mar 2022 Primary endpoint has been met. (Participants who have completed 120 day intervention with SGLT 2 inhibitor therapy will be evaluated for decrease in pancreatic and hepatic fat percentage, through MRI (3.0 Tesla). We hypothesise the usage of SGLT2 inhibitor will decrease 5% of liver and 1% of pancreatic fat content)
09 Mar 2022 Status changed to completed.
09 Mar 2022 Results published in the Journal of Clinical Endocrinology and Metabolism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com